MethylGene: Making multiple bets By Kathryn Calkins
Staff Writer

MethylGene Inc. believes in mitigating risk by taking multiple approaches to developing drugs for a given target, while also developing them in as many indications as possible. MethylGene's primary objective, said President and CEO Donald Corcoran, is to "get a target and take multiple cuts at it" using the company's three therapeutic development platforms: antisense, hairpin oligonucleotides and rationally designed small molecules.